C4 therapeutics to present at the american association for cancer research (aacr) annual meeting 2022

- clinical data from cohort a of the ongoing phase 1/2 trial of cft7455, a novel ikzf1/3 degrader, accepted as late-breaker poster presentation –

CCCC Ratings Summary

CCCC Quant Ranking